Panel backs Galleri blood test

An FDA advisory committee recommended approving Galleri, a blood test made by Grail that screens for up to fifty forms of cancer in people aged fifty and over.

Test detects cancers not routinely screened

Galleri can identify most cancers that doctors do not currently screen for routinely. The test uses a simple blood draw to look for genetic material and cancer markers.

Currently costs nine hundred forty-nine dollars

Galleri is already available by prescription and costs nine hundred forty-nine dollars. FDA approval could lead to insurance reimbursement and broader access.

Hundreds of companies pursuing blood cancer tests

Many companies are developing blood tests to detect cancer earlier, which could make screening easier to access in rural areas and other underserved regions.

Grail says test is additive, not replacement

Grail states Galleri should be used alongside standard screenings like colonoscopies and mammograms, not instead of them.

Clinical trials showed mixed results

In two large trials, Galleri often failed to detect early-stage cancers and did not reduce overall mortality or meet its primary endpoint of reducing Stage three and four cancers combined.

Cancer Institute director warns of false security

Phil Castle, director of the National Cancer Institute's Division of Cancer Prevention, told the panel that approval could give people false confidence and waste resources.

“Routine approval and broad population rollout would risk harm and waste resources.”

Panel recommends cautious marketing language

The FDA panel recommended Galleri's marketing avoid calling it an early detection tool and include warnings that negative results do not rule out cancer.

Medicare coverage boosts financial incentives

Congress approved Medicare coverage for multi-cancer detection tests approved by the FDA, making approval far more valuable financially and prompting the agency to expedite Galleri's review.

Galleri seen as industry bellwether

Cristian Tomasetti, director of City of Hope's early detection division, says Galleri's approval would validate the entire concept of blood-based multi-cancer screening.

“It's a new era for early cancer detection, and if the FDA approves it, it validates the overall concept.”

Experts debate whether studies truly failed

Tomasetti argues the three-year study period was too short to measure mortality benefits, which typically take decades. He says the data still show promise despite missing initial endpoints.

No timeline for FDA final decision

The FDA has not indicated when it will make a final decision on Galleri, though the panel's recommendation suggests approval is likely.